Printer Friendly
The Free Library
14,506,614 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Syneron's Vela System Receives CE Mark Approval for Cellulite Treatment.


YOKNEAM, Israel & GRUNWALD, Germany -- Syneron Medical Ltd. (Nasdaq:ELOS), and its European subsidiary Syneron GmbH, today announced that Syneron has been granted Medical CE Mark 0344 approval of its Vela vela

plural of velum.
(TM) system for non-invasive cellulite cel·lu·lite
n.
A fatty deposit causing a dimpled or uneven appearance, as around the thighs.


Cellulite
Cellulite is dimply skin caused by uneven fat deposits beneath the surface.
 treatment.

The Vela system is based on Syneron's proprietary ELOS(TM) (Electro-Optical Synergy Electro-Optical Synergy (ELOS) is a selective photothermolysis technology using various forms of energy frequencies principally for cosmetic medicial purposes developed by the corporation Syneron. ) combined energy technology, which uses Bi-Polar Radio Frequency and light energies to treat a wide range of medical aesthetic conditions. Utilizing a unique combination of RF energy, infrared light Noun 1. infrared light - electromagnetic radiation with wavelengths longer than visible light but shorter than radio waves
infrared emission, infrared radiation, infrared
, tissue mobilization and suction, Vela safely and effectively re-contours the skin surface.

"This unique medical CE Mark further proves that Syneron products meet the exacting quality and efficacy standards of the international medical community," said Hans Edel, Managing Director of Syneron GmbH. "With this latest regulatory approval, Syneron is able to market the widest offering of products in Europe of any medical aesthetic company."

The Vela system will be launched at the EADV EADV European Academy of Dermatology and Venereology  (European Academy of Dermatology & Venereology venereology /ve·ne·re·ol·o·gy/ (-ol´ah-je) the study and treatment of venereal diseases.

ve·ne·re·ol·o·gy
n.
The study of sexually transmitted diseases.
) conference in Florence, Italy, November 17-21, 2004.

About Syneron Medical Ltd.

Syneron Medical Ltd. (NASDAQ: ELOS) manufactures and distributes medical aesthetic devices that are powered by the proprietary, patented ELOS combined-energy technology of Bi-Polar Radio Frequency and Light. The Company's innovative ELOS technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications, including hair removal, wrinkle Wrinkle

A feature of a new product or security intended to entice a buyer.
 reduction, rejuvenating the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. is located in Israel. Syneron has offices and distributors throughout the world, including North American North American

named after North America.


North American blastomycosis
see North American blastomycosis.

North American cattle tick
see boophilusannulatus.
 Headquarters in Canada, European Headquarters in Germany, and Asia-Pacific Headquarters in Hong Kong Hong Kong (hŏng kŏng), Mandarin Xianggang, special administrative region of China, formerly a British crown colony (2005 est. pop. 6,899,000), land area 422 sq mi (1,092 sq km), adjacent to Guangdong prov. , which provide sales, service and support. Additional information can be found at www.syneron.com.

For more information, please contact Hans Edel, Managing Director, Syneron GmbH., at Tel. +49 89 6424810 or email: infode@syneron-med.com.
Syneron Medical Ltd.
Soltam Technology Park
P.O.B. 550
Yokneam Illit, 20692
Israel
Tel: +972 4 909-6200
Fax: +972 4 909-6202
info@syneron-med.com

Syneron GmbH
7 Ludwig
Ganghofer Str.
D-82031 Grunwald
Germany
Tel: +49 89 6424810
Fax: +49 89 64248170
infode@syneron-med.com


Syneron, the Syneron logo, Vela, the Vela logo and ELOS are trademarks of Syneron Medical Ltd. and may be registered in certain jurisdictions. ELOS (Electro-Optical Synergy) is a proprietary technology of Syneron Medical. All other names are the property of their respective owners.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1CANA
Date:Nov 15, 2004
Words:416
Previous Article:Analog Devices Adds W-CDMA/UMTS Chipset to Arsenal of Technologies for 3G Cellular Handsets.
Next Article:WJ Communications to Present at Wells Fargo Securities Technology Forum; Presentation to be Web cast at 12:30 p.m. EST on November 18, 2004.
Topics:



Related Articles
GUIDANT'S INTRAVASCULAR RADIOTHERAPY MEETS EUROPEAN GOAL.
FDA Approves Syneron Aurora for Acne Treatment.
Syneron to Present at CIBC World Markets Healthcare Conference.
FDA Clears Syneron's Comet and Polaris DS Systems for Permanent Hair Reduction on all Skin Types.
FDA Requests Resubmission of Syneron Medical's VelaSmooth Device under PMA Guidelines.
Syneron Responds to News of Thermage's Belated Addition of Patents to Lawsuit.
Syneron Prices Secondary Offering at $28.00 Per Share.
Syneron Announces Closing of Secondary Offering.
Syneron Announces Closing of Over-Allotment Shares in Secondary Offering.
SFDA GRANTS MIRACLE LASER APPROVAL TO SELL SYNERON PRODUCTS.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles